Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HND032
- Development stage
- Preclinical
- Lead developer
- Handa Pharmaceuticals
- Modality
- Small Molecules
01
Overview
HND032 is a small molecule generic drug candidate being developed by Handa Pharmaceuticals and its subsidiary, Handa Neuroscience. It is classified as a high-barrier generic targeting the central nervous system (CNS), specifically for the treatment of smoking cessation. The drug is currently in the development stage, with ongoing Chemistry, Manufacturing, and Controls (CMC) and Bioequivalence (BE) studies. While the specific reference listed drug (RLD) and active pharmaceutical ingredient have not been publicly disclosed, HND032 is part of Handa's specialty portfolio focusing on complex generic formulations and high-barrier-to-entry products.
Beyond the preview
Go deeper on HND032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HND032.